Form D · Biotechnology
Keystone Bio, Inc.
St. Louis, MO · CIK 0001774842
Offering snapshot reported Apr 29, 2019 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $5M Reported outside-investor minimum
- First sale
- Apr 22, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 29, 2019 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-338327
Source: Form D, filed Apr 29, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Hugley | Director |
| Peter Nara | Director |
| Marc Penn | Director |
| Daniel Sindelar | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Cambridge Innovation Center 4220 Duncan Ave., Suite 200
St. Louis, MO, 63110
St. Louis, MO, 63110